The pharmaceutical industry is experiencing a surge in the sales of injectable GLP-1 drugs for weight loss, with Eli Lilly's Zepbound recently surpassing Novo Nordisk's Wegovy in new U.S. prescriptions.

The trial will assess the efficacy of BioInvent's monoclonal antibody, BI-1910, when used in conjunction with Merck's KEYTRUDA® (pembrolizumab)

FG-3246 has shown promising results in treating adenocarcinoma within a heavily pre-treated patient group.

Kiromic BioPharma, Inc. has announced early indications of tumor stabilization in a patient enrolled in the Deltacel-01 Phase 1 clinical trial.

NANOBIOTIX has completed the dose escalation phase of a Phase 1 study evaluating NBTXR3, a potential first-in-class radioenhancer.

Corbus Pharmaceuticals, a precision oncology firm, has initiated a Phase 1 clinical trial in the U.S. for CRB-701 (SYS6002)

A clinical trial for a gene-editing treatment by Verve Therapeutics, known as VERVE-101, has been halted after a participant experienced severe side effects.

In a significant medical advancement, Ractigen Therapeutics has initiated its first-ever human clinical trial for RAG-01, a novel small activating RNA (saRNA) treatment for NMIBC.

Verismo Therapeutics, a company specializing in CAR T-cell therapies, is progressing with its second clinical trial using the SynKIR™ platform.

Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927.

Achilles Therapeutics plc has reported interim Phase I/IIa clinical trial data for clonal neoantigen reactive T cells (cNeT) from the CHIRON study for non-small cell lung cancer (NSCLC) and the THETIS study for malignant melanoma

This innovative vaccine, developed by CureVac, is multivalent and contains antigens that match the four flu strains recommended by the World Health Organization (WHO).